Baseline characteristics of study cohorts with MPN-BP and post-MDS AML
| Characteristic . | MPN-BP . | Post-MDS AML . | P . |
|---|---|---|---|
| No. of patients | 177 | 1104 | |
| No. of centers | 73 | 165 | |
| Patient-related | |||
| Age at HCT, y | .78* | ||
| Median (min-max) | 59 (40-82) | 59 (40-76) | |
| Age at HCT, n (%), y | .31† | ||
| 40-49 | 30 (17) | 196 (18) | |
| 50-59 | 73 (41) | 429 (39) | |
| 60-69 | 59 (33) | 419 (38) | |
| ≥70 | 15 (8) | 60 (5) | |
| Sex, n (%) | .30† | ||
| Male | 116 (66) | 679 (62) | |
| Female | 61 (34) | 425 (38) | |
| Karnofsky score, n (%) | .53† | ||
| 90-100 | 88 (50) | 579 (52) | |
| <90 | 84 (47) | 481 (44) | |
| Missing | 5 (3) | 44 (4) | |
| HCT-CI, n (%) | .14† | ||
| 0 | 33 (19) | 175 (16) | |
| 1-2 | 31 (18) | 195 (18) | |
| ≥3 | 50 (28) | 240 (22) | |
| N/A, before 2007 | 61 (34) | 469 (42) | |
| Missing | 2 (1) | 25 (2) | |
| Disease-related | |||
| Etiology of MPN at original diagnosis, n (%) | |||
| PV | 46 (26) | 0 (0.0) | |
| ET | 51 (29) | 0 (0.0) | |
| PMF | 60 (34) | 0 (0.0) | |
| MPN-U | 20 (11) | 0 (0.0) | |
| N/A | 0 (0.0) | 1104 (100) | |
| Time between diagnosis of MPN/MDS and AML, n (%), y | |||
| Median (min-max) | 3 (0.0-30) | 0.3 (0.0-23) | |
| <2 | 70 (40) | 764 (69) | |
| 2-5 | 28 (16) | 71 (6) | |
| >5 | 63 (36) | 29 (3) | |
| Missing | 16 (9) | 240 (22) | |
| WBC at diagnosis, n (%), ×109/L | <.01† | ||
| <30 | 121 (68) | 894 (81) | |
| 30-100 | 31 (18) | 95 (9) | |
| >100 | 9 (5) | 21 (2) | |
| Missing | 16 (9) | 94 (9) | |
| Cytogenetics, n (%) | .76† | ||
| Favorable | 1 (<1) | 14 (1) | |
| Intermediate | 96 (54) | 642 (58) | |
| Poor | 67 (38) | 371 (34) | |
| Not tested | 5 (3) | 29 (3) | |
| Missing | 8 (5) | 48 (4) | |
| Disease status at HCT, n (%) | .21† | ||
| In remission‡ | 101 (57) | 685 (62) | |
| Active leukemia§ | 76 (43) | 419 (38) | |
| Time from diagnosis to HCT, median (min-max) | 5 (0.3-321) | 5 (0.2-108) | .13* |
| Time from diagnosis of AML to HCT, n (%), mo | .43† | ||
| <6 | 105 (59) | 681 (62) | |
| 6-12 | 38 (21) | 253 (23) | |
| >2 | 34 (19) | 170 (15) | |
| Therapy-related, n (%) | |||
| Induction therapy | .30† | ||
| 7+3 ± other | 100 (56) | 568 (51) | |
| Cytarabine based | 18 (10) | 99 (9) | |
| Hypomethylating | 7 (4) | 41 (4) | |
| Other | 3 (2) | 62 (6) | |
| No therapy given | 11 (6) | 69 (6) | |
| Missing | 38 (21) | 265 (24) | |
| Transplant-related | |||
| Graft source, n (%) | .15† | ||
| Bone marrow | 22 (12) | 185 (17) | |
| Peripheral blood | 155 (88) | 919 (83) | |
| Donor type, n (%) | .47† | ||
| HLA-identical sibling | 54 (31) | 344 (31) | |
| Other related | 13 (7) | 51 (5) | |
| Well-matched URD | 83 (47) | 522 (47) | |
| Partially matched/mismatched URD | 27 (15) | 187 (17) | |
| D-R sex match, n (%) | .84† | ||
| M-M | 76 (43) | 464 (42) | |
| M-F | 36 (20) | 250 (23) | |
| F-M | 39 (22) | 212 (19) | |
| F-F | 25 (14) | 174 (16) | |
| Missing | 1 (<1) | 4 (<1) | |
| D-R CMV status, n (%) | .12† | ||
| +/+ | 49 (28) | 344 (31) | |
| +/− | 13 (7) | 104 (9) | |
| −/+ | 58 (33) | 382 (35) | |
| −/− | 53 (30) | 235 (21) | |
| Missing | 4 (2) | 39 (4) | |
| Conditioning regimen, n (%) | .54† | ||
| TBI-MAC | 21 (12) | 157 (14) | |
| Chemo-MAC | 72 (41) | 408 (37) | |
| RIC/NST | 84 (47) | 539 (49) | |
| GVHD prophylaxis, n (%) | .38† | ||
| CNI + MMF ± others | 47 (27) | 313 (28) | |
| CNI + MTX ± others | 99 (56) | 619 (56) | |
| CNI ± others | 19 (11) | 118 (11) | |
| Post-CY | 10 (6) | 30 (3) | |
| Other | 1 (<1) | 16 (1) | |
| Missing | 1 (<1) | 8 (<1) | |
| In vivo T-cell depletion, n (%) | .05† | ||
| No | 131 (74) | 735 (67) | |
| Yes | 46 (26) | 369 (33) | |
| Planned G-CSF/GM-CSF within 7 d post-HCT, n (%) | .18† | ||
| No | 129 (73) | 844 (76) | |
| Yes | 46 (26) | 231 (21) | |
| Missing | 2 (1) | 29 (3) | |
| Year of transplant, n (%) | <.01† | ||
| 2001-2005 | 39 (22) | 347 (31) | |
| 2006-2010 | 72 (41) | 489 (44) | |
| 2011-2015 | 66 (37) | 268 (24) | |
| Follow-up, median (min-max) | 71 (14-169) | 94 (3-193) |
| Characteristic . | MPN-BP . | Post-MDS AML . | P . |
|---|---|---|---|
| No. of patients | 177 | 1104 | |
| No. of centers | 73 | 165 | |
| Patient-related | |||
| Age at HCT, y | .78* | ||
| Median (min-max) | 59 (40-82) | 59 (40-76) | |
| Age at HCT, n (%), y | .31† | ||
| 40-49 | 30 (17) | 196 (18) | |
| 50-59 | 73 (41) | 429 (39) | |
| 60-69 | 59 (33) | 419 (38) | |
| ≥70 | 15 (8) | 60 (5) | |
| Sex, n (%) | .30† | ||
| Male | 116 (66) | 679 (62) | |
| Female | 61 (34) | 425 (38) | |
| Karnofsky score, n (%) | .53† | ||
| 90-100 | 88 (50) | 579 (52) | |
| <90 | 84 (47) | 481 (44) | |
| Missing | 5 (3) | 44 (4) | |
| HCT-CI, n (%) | .14† | ||
| 0 | 33 (19) | 175 (16) | |
| 1-2 | 31 (18) | 195 (18) | |
| ≥3 | 50 (28) | 240 (22) | |
| N/A, before 2007 | 61 (34) | 469 (42) | |
| Missing | 2 (1) | 25 (2) | |
| Disease-related | |||
| Etiology of MPN at original diagnosis, n (%) | |||
| PV | 46 (26) | 0 (0.0) | |
| ET | 51 (29) | 0 (0.0) | |
| PMF | 60 (34) | 0 (0.0) | |
| MPN-U | 20 (11) | 0 (0.0) | |
| N/A | 0 (0.0) | 1104 (100) | |
| Time between diagnosis of MPN/MDS and AML, n (%), y | |||
| Median (min-max) | 3 (0.0-30) | 0.3 (0.0-23) | |
| <2 | 70 (40) | 764 (69) | |
| 2-5 | 28 (16) | 71 (6) | |
| >5 | 63 (36) | 29 (3) | |
| Missing | 16 (9) | 240 (22) | |
| WBC at diagnosis, n (%), ×109/L | <.01† | ||
| <30 | 121 (68) | 894 (81) | |
| 30-100 | 31 (18) | 95 (9) | |
| >100 | 9 (5) | 21 (2) | |
| Missing | 16 (9) | 94 (9) | |
| Cytogenetics, n (%) | .76† | ||
| Favorable | 1 (<1) | 14 (1) | |
| Intermediate | 96 (54) | 642 (58) | |
| Poor | 67 (38) | 371 (34) | |
| Not tested | 5 (3) | 29 (3) | |
| Missing | 8 (5) | 48 (4) | |
| Disease status at HCT, n (%) | .21† | ||
| In remission‡ | 101 (57) | 685 (62) | |
| Active leukemia§ | 76 (43) | 419 (38) | |
| Time from diagnosis to HCT, median (min-max) | 5 (0.3-321) | 5 (0.2-108) | .13* |
| Time from diagnosis of AML to HCT, n (%), mo | .43† | ||
| <6 | 105 (59) | 681 (62) | |
| 6-12 | 38 (21) | 253 (23) | |
| >2 | 34 (19) | 170 (15) | |
| Therapy-related, n (%) | |||
| Induction therapy | .30† | ||
| 7+3 ± other | 100 (56) | 568 (51) | |
| Cytarabine based | 18 (10) | 99 (9) | |
| Hypomethylating | 7 (4) | 41 (4) | |
| Other | 3 (2) | 62 (6) | |
| No therapy given | 11 (6) | 69 (6) | |
| Missing | 38 (21) | 265 (24) | |
| Transplant-related | |||
| Graft source, n (%) | .15† | ||
| Bone marrow | 22 (12) | 185 (17) | |
| Peripheral blood | 155 (88) | 919 (83) | |
| Donor type, n (%) | .47† | ||
| HLA-identical sibling | 54 (31) | 344 (31) | |
| Other related | 13 (7) | 51 (5) | |
| Well-matched URD | 83 (47) | 522 (47) | |
| Partially matched/mismatched URD | 27 (15) | 187 (17) | |
| D-R sex match, n (%) | .84† | ||
| M-M | 76 (43) | 464 (42) | |
| M-F | 36 (20) | 250 (23) | |
| F-M | 39 (22) | 212 (19) | |
| F-F | 25 (14) | 174 (16) | |
| Missing | 1 (<1) | 4 (<1) | |
| D-R CMV status, n (%) | .12† | ||
| +/+ | 49 (28) | 344 (31) | |
| +/− | 13 (7) | 104 (9) | |
| −/+ | 58 (33) | 382 (35) | |
| −/− | 53 (30) | 235 (21) | |
| Missing | 4 (2) | 39 (4) | |
| Conditioning regimen, n (%) | .54† | ||
| TBI-MAC | 21 (12) | 157 (14) | |
| Chemo-MAC | 72 (41) | 408 (37) | |
| RIC/NST | 84 (47) | 539 (49) | |
| GVHD prophylaxis, n (%) | .38† | ||
| CNI + MMF ± others | 47 (27) | 313 (28) | |
| CNI + MTX ± others | 99 (56) | 619 (56) | |
| CNI ± others | 19 (11) | 118 (11) | |
| Post-CY | 10 (6) | 30 (3) | |
| Other | 1 (<1) | 16 (1) | |
| Missing | 1 (<1) | 8 (<1) | |
| In vivo T-cell depletion, n (%) | .05† | ||
| No | 131 (74) | 735 (67) | |
| Yes | 46 (26) | 369 (33) | |
| Planned G-CSF/GM-CSF within 7 d post-HCT, n (%) | .18† | ||
| No | 129 (73) | 844 (76) | |
| Yes | 46 (26) | 231 (21) | |
| Missing | 2 (1) | 29 (3) | |
| Year of transplant, n (%) | <.01† | ||
| 2001-2005 | 39 (22) | 347 (31) | |
| 2006-2010 | 72 (41) | 489 (44) | |
| 2011-2015 | 66 (37) | 268 (24) | |
| Follow-up, median (min-max) | 71 (14-169) | 94 (3-193) |